Company: Axial Biotherapeutics
Job title: Co-Founder, CEO & Director
|Dr. Donabedian is an accomplished business development and strategy executive with extensive leadership experience. Dr. Donabedian has a track record of building companies, most recently as a Venture Partner at Longwood Fund.
Prior to joining Longwood, Dr. Donabedian has held various leadership roles at biopharmaceutical companies including AbbVie and GSK. At AbbVie, Dr. Donabedian served as Vice President & Global Head of Ventures and Early Stage Collaborations where he led a global team that completed significant transactions across multiple therapeutic areas and stages of development. Prior to AbbVie, Dr. Donabedian served as Vice President Global New Deal Strategy and Development at GlaxoSmithKline, and Senior Manager at Accenture’s Strategic Services Consulting Group.
He holds a BA in Chemistry from St. Anselm College, a Ph.D. in Polymer Chemistry from the University of Massachusetts Lowell, and an MBA from the University of North Carolina. He currently serves on the Board of Alcyone Life Sciences, a privately held CNS company which he co-founded.
Clinical Study Design Considerations for the Testing of Gut Retentive Products, such as AB-2004, in the Neurological Disease Setting 1:30 pm
day: Day Two
Microbiome GBA Industry & Academic Leaders Panel Discussion – Providing an Overview of the Status & Direction of the Microbiome GBA Space 8:30 am
• Providing a bird’s eye view on scientific and product development progress made in the microbiome gut-brain axis space – what is the status of this field? • Reviewing gaps in our knowledge of neurogastroenterology and hot pockets of innovation opportunity in the microbiome-GBA space • Plotting the road to success: what is our end…Read more
day: Day One